Consistent Financial Performance
Third quarter adjusted operating income was $517 million, and adjusted earnings per share were $2.51, consistent with internal expectations.
Strong Clinical Research Contributions
DaVita Clinical Research maintains over 250 research sites, has conducted more than 500 clinical trials, and contributed to the FDA approval of dozens of ESKD drugs.
Investment in Technology and Innovation
Continued investments in technology infrastructure, including AI solutions, to improve clinical care and drive long-term cost efficiencies.
Share Repurchase Program
Year-to-date repurchases of approximately 10 million shares, representing about $1.5 billion.